Supplementary Figure S10 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma

Sean R. Corcoran; James D. Phelan; Jaewoo Choi; Galina Shevchenko; Rachel E. Fenner; Xin Yu; Sebastian Scheich; Tony Hsiao; Vivian M. Morris; Evangelia K. Papachristou; Kamal Kishore; Clive S. D’Santos; Yanlong Ji; Stefania Pittaluga; George W. Wright; Henning Urlaub; Kuan‐Ting Pan; Thomas Oellerich; Jagan Muppidi; Daniel J. Hodson; Louis M. Staudt

doi:10.1158/2159-8290.26935124.v1

Abstract

KLHL6 loss does not score as a negative regulator of surface CD79B or Pola-V sensitivity in CRISPR screens of ABC DLBCL cell lines and KLHL6 loss does not sensitize to MMAE

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Corcoran et al. (2024) studied this question.

synapsesocial.com/papers/68e59691b6db6435875313be https://doi.org/10.1158/2159-8290.26935124.v1

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S10 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma

Abstract

Discussion

Cite This Study

Supplementary Figure S10 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers